---
annotations:
- type: Pathway Ontology
  value: signaling pathway
- type: Pathway Ontology
  value: kinase mediated signaling pathway
authors:
- ReactomeTeam
- Anwesha
- Ryanmiller
description: Signaling by AKT is one of the key outcomes of receptor tyrosine kinase
  (RTK) activation. AKT is activated by the cellular second messenger PIP3, a phospholipid
  that is generated by PI3K. In ustimulated cells, PI3K class IA enzymes reside in
  the cytosol as inactive heterodimers composed of p85 regulatory subunit and p110
  catalytic subunit. In this complex, p85 stabilizes p110 while inhibiting its catalytic
  activity. Upon binding of extracellular ligands to RTKs, receptors dimerize and
  undergo autophosphorylation. The regulatory subunit of PI3K, p85, is recruited to
  phosphorylated cytosolic RTK domains either directly or indirectly, through adaptor
  proteins, leading to a conformational change in the PI3K IA heterodimer that relieves
  inhibition of the p110 catalytic subunit. Activated PI3K IA phosphorylates PIP2,
  converting it to PIP3; this reaction is negatively regulated by PTEN phosphatase.
  PIP3 recruits AKT to the plasma membrane, allowing TORC2 to phosphorylate a conserved
  serine residue of AKT. Phosphorylation of this serine induces a conformation change
  in AKT, exposing a conserved threonine residue that is then phosphorylated by PDPK1
  (PDK1). Phosphorylation of both the threonine and the serine residue is required
  to fully activate AKT. The active AKT then dissociates from PIP3 and phosphorylates
  a number of cytosolic and nuclear proteins that play important roles in cell survival
  and metabolism. For a recent review of AKT signaling, please refer to Manning and
  Cantley, 2007.   View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=1257604
  Reactome].
last-edited: 2021-01-25
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP2653
- /instance/WP2653
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP2653.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: Signaling by AKT is one of the key outcomes of receptor tyrosine kinase
    (RTK) activation. AKT is activated by the cellular second messenger PIP3, a phospholipid
    that is generated by PI3K. In ustimulated cells, PI3K class IA enzymes reside
    in the cytosol as inactive heterodimers composed of p85 regulatory subunit and
    p110 catalytic subunit. In this complex, p85 stabilizes p110 while inhibiting
    its catalytic activity. Upon binding of extracellular ligands to RTKs, receptors
    dimerize and undergo autophosphorylation. The regulatory subunit of PI3K, p85,
    is recruited to phosphorylated cytosolic RTK domains either directly or indirectly,
    through adaptor proteins, leading to a conformational change in the PI3K IA heterodimer
    that relieves inhibition of the p110 catalytic subunit. Activated PI3K IA phosphorylates
    PIP2, converting it to PIP3; this reaction is negatively regulated by PTEN phosphatase.
    PIP3 recruits AKT to the plasma membrane, allowing TORC2 to phosphorylate a conserved
    serine residue of AKT. Phosphorylation of this serine induces a conformation change
    in AKT, exposing a conserved threonine residue that is then phosphorylated by
    PDPK1 (PDK1). Phosphorylation of both the threonine and the serine residue is
    required to fully activate AKT. The active AKT then dissociates from PIP3 and
    phosphorylates a number of cytosolic and nuclear proteins that play important
    roles in cell survival and metabolism. For a recent review of AKT signaling, please
    refer to Manning and Cantley, 2007.   View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=1257604
    Reactome].
  keywords:
  - 'p-Y307-PPP2CB '
  - p-S15,S356-RPS6KB2
  - p-S196-CASP9(1-416)
  - 'ER alpha46 '
  - p-T,p-S-AKT
  - AKT/AKT1 E17K mutant
  - Cell Receptor (BCR)
  - 'KL-1 '
  - 'FGF23(25-251) '
  - ADP
  - PHLPP (Mn2+
  - p-T23-CHUK
  - 'GSK3A '
  - 'IL1RL1 '
  - estrogen signaling
  - PI5P
  - 'EGF '
  - TCR signaling
  - PP2A-B56-beta,gamma
  - 'p-Y307-PPP2CA '
  - 'Mn2+ '
  - 'MLST8 '
  - Signaling by FGFR
  - 'p-S474-AKT2 '
  - Signaling by EGFR
  - 'VAV1 '
  - 'AKT '
  - PI4P
  - 'Activator:PI3K '
  - 'FGF19 '
  - CREB1
  - 'PIP5K1A '
  - 'FGF6 '
  - 'ESR1 '
  - 'p-Y1234,Y1235,Y1349,Y1356-MET '
  - 'p-T305-AKT3 '
  - 'HGF(32-494) '
  - 'p-T145-CDKN1A '
  - Degradation
  - 'p-6Y-ERBB2 '
  - IER3
  - 'BEZ235 '
  - 'PDGFA-1 '
  - 'BTC(32-111) '
  - 'p-S337-PPP2R5C '
  - E17K mutant:PIP2
  - 'p-7Y,Y1112-ERBB2 '
  - ERBB2 becomes activated by forming a heterodimer with another ligand-activated
    EGFR family member, either EGFR, ERBB3 or ERBB4, which is accompanied by dissociation
    of chaperoning proteins HSP90 and CDC37 (Citri et al. 2004), as well as ERBB2IP
    (Borg et al. 2000) from ERBB2. ERBB2 heterodimers function to promote cell proliferation,
    cell survival and differentiation, depending on the cellular context. ERBB2 can
    also be activated by homodimerization when it is overexpressed, in cancer for
    example. <br><br>
  - 'Autophosphorylated FLT3 '
  - 'FGF20 '
  - 'FOXO4 '
  - 'EGF-like ligands '
  - 'KL-2 '
  - In cells expressing ERBB2 and ERBB4, ligand stimulated ERBB4 can either homodimerize
    or form heterodimers with ERBB2 (Li et al. 2007), resulting in trans-autophosphorylation
    of ERBB2 and ERBB4 on C-tail tyrosine residues that will subsequently serve as
    docking sites for downstream signaling molecules, leading to activation of RAF/MAP
    kinase cascade and, in the case of ERBB4 CYT1 isoforms, PI3K-induced AKT signaling
    (Hazan et al. 1990, Cohen et al. 1996, Li et al. 2007, Kaushansky et al. 2008).
    Signaling by ERBB4 is downregulated by the action of WWP1 and ITCH ubiquitin ligases,
    and is shown under Signaling by ERBB4.
  - 'Activated FGFR2b homodimer bound to FGF '
  - 'PPP2R1B '
  - E17K
  - PI3K alpha
  - Signaling by ERBB4
  - 'p-6Y,Y1112-ERBB2 '
  - 'p-T32,S253,S315-FOXO3 '
  - 'p-Y-IRS1 '
  - 'p-8Y-FGFR1c '
  - 'p-T308,S473-AKT1 '
  - PTEN Regulation
  - cofactor)
  - mutant:PIP2
  - PIP5K1A-C
  - p-S-AKT:PDPK1:PIP3
  - cascade
  - 'p-5Y-GAB1 '
  - p-S99-BAD
  - 'FGF17-1 '
  - G1/S transition
  - 'p-S473-AKT1 '
  - IL33:IL1RL1:IL1RAP-1:MYD88 dimer:IRAK1,IRAK4,TRAF6
  - 'oxide: NOS3'
  - 'IL33 '
  - 'ESTG '
  - 'PDGFB(82-241) '
  - 'PPP2R5C '
  - 'HBEGF(63-148) '
  - PP2A
  - RAF/MAP kinase
  - AKT inhibitors:AKT
  - 'IRAK4 '
  - p-S109-MKRN1
  - PP2A-B56-beta,gamma:IER3:p-T,Y-MAPK dimers
  - 'p-6Y-EGFR '
  - AKT:PIP3
  - 'p-4Y-PIK3AP1 '
  - PTEN
  - 'PPP2CB '
  - for Apoptosis
  - AKT
  - 'AKT2 '
  - 'p-T26,S184-FOXO6 '
  - p-S473-AKT1 E17K
  - 'RICTOR '
  - 'FGF10 '
  - Extra-nuclear
  - 'HGF(495-728) '
  - 'FYN '
  - 'p-Y180-ICOS '
  - 'NRG1 '
  - AKT1 E17K
  - 'p-Y-ERBB2 '
  - Signaling by NTRKs
  - 'p-S9-GSK3B '
  - 'EPGN(23-154) '
  - 'p-Y63,Y79,Y110-TRAT1 '
  - ATP
  - Activator:PI3K
  - 'p-Y,Y877-ERBB2 '
  - 'FGF8-1 '
  - 'THEM4 '
  - 'PPP2R5D '
  - p-T-CDKN1A/B
  - '2xHC-INS(25-54) '
  - p-S351-NR4A1
  - Regulation of TP53
  - PI3K inhibitors
  - 'TGFA(24-98) '
  - 'MyrG-p-Y419-SRC '
  - '4xHC-INS(90-110) '
  - 'p-S368-PPP2R5B '
  - PI3K Inhibitors:PI3K
  - 'GAB1 '
  - 'KLB '
  - PP2A-A:PP2A-C
  - 'p-S473-AKT1 E17K '
  - AKT:PIP3:THEM4/TRIB3
  - Signaling by the B
  - PI3K
  - 'PDGFA-2 '
  - 'LCK '
  - 'MTOR '
  - 'CD80 '
  - 'p-6Y-FGFR3c '
  - p-T,Y MAPK dimers
  - 'p-T309,S474-AKT2 '
  - 'p-T202,Y204-MAPK3 '
  - TSC2
  - p-S9/21-GSK3
  - 'MYD88 '
  - 'PPP2R1A '
  - 'p-5Y-FGFR4 '
  - 'PI(4,5)P2 '
  - activation and
  - 'HS '
  - 'IL1RAP-1 '
  - Metabolism of nitric
  - NR4A1
  - p-S939,T1462-TSC2
  - 'IER3 '
  - TORC2 complex
  - 'ER alpha36 '
  - Signaling by PDGF
  - 'STRN '
  - 'CD86 '
  - 'PPP2CA '
  - 'p-T309-AKT2 '
  - 'FGF9 '
  - 'p-Y1056,Y1188,Y1242-ERBB4 JM-A CYT-1 isoform '
  - 'p-6Y-FGFR3b '
  - Activated
  - 'KITLG-1(26-190) '
  - FOXO1,FOXO3,FOXO4,(FOXO6)
  - 'Activated FGFR2c homodimer bound to FGF '
  - regulation
  - 'INSR(28-758) '
  - Pi
  - 'PIK3CB '
  - 'p-6Y-CD19 '
  - 'p-T185,Y187-MAPK1 '
  - 'p-T308-AKT1 '
  - 'p-T24,S256,S319-FOXO1 '
  - 'p-11Y-PDGFRA '
  - Signaling by ERBB2
  - 'PIK3CD '
  - In cells expressing ERBB2 and ERBB3, ERBB3 activated by neuregulin NRG1 or NRG2
    binding (Tzahar et al. 1994) forms a heterodimer with ERBB2 (Pinkas-Kramarski
    et al. 1996, Citri et al. 2004). ERBB3 is the only EGFR family member with no
    kinase activity, and can only function in heterodimers, with ERBB2 being its preferred
    heterodimerization partner. After heterodimerization, ERBB2 phosphorylates ten
    tyrosine residues in the C-tail of ERBB3, Y1054, Y1197, Y1199, Y1222, Y1224, Y1260,
    Y1262, Y1276, Y1289 and Y1328 (Prigent et al. 1994, Pinkas-Kramarski et al. 1996,
    Vijapurkar et al. 2003, Li et al. 2007) that subsequently serve as docking sites
    for downstream signaling molecules, resulting in activation of PI3K-induced AKT
    signaling and RAF/MAP kinase cascade. Signaling by ERBB3 is downregulated by the
    action of RNF41 ubiquitin ligase, also known as NRDP1. <br><br>
  - 'MAPKAP1 '
  - AKT inhibitors
  - 'GRB2-1 '
  - In cells expressing both ERBB2 and EGFR, EGF stimulation of EGFR leads to formation
    of both ERBB2:EGFR heterodimers (Wada et al. 1990, Karunagaran et al. 1996) and
    EGFR homodimers. Heterodimers of ERBB2 and EGFR trans-autophosphorylate on twelve
    tyrosine residues, six in the C-tail of EGFR and six in the C-tail of ERBB2 -
    Y1023, Y1139, Y1196, Y1221, Y1222 and Y1248 (Margolis et al. 1989, Hazan et al.
    1990,Walton et  al. 1990, Helin et al. 1991, Ricci et al. 1995, Pinkas-Kramarski
    1996). Phosphorylated tyrosine residues in the C-tail of EGFR and ERBB2 serve
    as docking sites for downstream signaling molecules. Three key signaling pathways
    activated by ERBB2:EGFR heterodimers are RAF/MAP kinase cascade, PI3K-induced
    AKT signaling, and signaling by phospholipase C gamma (PLCG1). Downregulation
    of EGFR signaling is mediated by ubiquitin ligase CBL, and is shown under Signaling
    by EGFR.<br><br>
  - 'p-Y419-SRC-1 '
  - PDPK1:PIP3
  - 'FOXO1 '
  - H2O
  - 'p-6Y-INSR(763-1382) '
  - Costimulation by the
  - p-T308,S473-AKT1
  - 'PIK3R1 '
  - 'TRIB3 '
  - 'RAC2 '
  - 'TRAF6 '
  - Expression and
  - 'FGF1 '
  - 'GSK3B '
  - p-S368-PPP2R5B,p-S337-PPP2R5C
  - 'p-S21-GSK3A '
  - THEM4/TRIB3
  - 'PIP5K1C '
  - Signaling by SCF-KIT
  - PI(4,5)P2
  - 'PDGFB (82-190) '
  - MDM2
  - PDPK1
  - 'p-8Y-FGFR1b '
  - 'p-10Y-ERBB3-1 '
  - 'RHOG '
  - Signaling by MET
  - 'IRAK1 '
  - 'PIP4K2C '
  - 'FGF18 '
  - 'p-T305,S472-AKT3 '
  - PI(3,4,5)P3
  - p-S166,S188-MDM2
  - MKRN1
  - Intrinsic Pathway
  - 'CDKN1A '
  - 'RAC1 '
  - PDPK1:PIP2
  - 'p-T32,S197,S262-FOXO4 '
  - 'PRR5 '
  - 'p-12Y-PDGFRB '
  - 'PIK3R2 '
  - 'FLT3LG '
  - 'PHLPP1 '
  - 'p-T157-CDKN1B '
  - 'AKT3 '
  - 'PPP2R5B '
  - MTOR signalling
  - 'PI3K mutants '
  - 'PDPK1 '
  - PDPK1:p-S473-AKT1
  - BAD
  - 'NRG2 '
  - 'PPP2R5E '
  - 'FGF4 '
  - GSK3
  - p-T24,S256,S319-FOXO1,p-T32,S253,S315-FOXO3,p-T32,S197,S262-FOXO4,(p-T26,S184-FOXO6)
  - 'AREG(101-187) '
  - 'GalNAc-T178-FGF23(25-251) '
  - 'p-Y-GAB2 '
  - 'EREG(60-108) '
  - CASP9(1-416)
  - 'PI(3,4,5)P3 '
  - p-T-AKT
  - 'p-7Y-KIT '
  - p-Y307-PP2A
  - 'PHLPP2 '
  - mutants,Activator:PI3K
  - RPS6KB2
  - 'MK2206 '
  - 'AKT1 E17K '
  - 'PIP4K2B '
  - 'FOXO3 '
  - 'p-Y-IRS2 '
  - 'p-Y191-CD28 '
  - RAC1:GTP,RAC2:GTP,RHOG:GTP:PI3K alpha
  - p-S133-CREB1
  - 'FGF3 '
  - AKT1
  - 'CDKN1B '
  - 'FGF16 '
  - 'FGF5-1 '
  - 'p-Y394-LCK '
  - 'PIK3R3 '
  - SRC,LCK,EGFR,INSR
  - 'GTP '
  - Mitotic G1 phase and
  - 'p-Y1046,Y1178,Y1232-ERBB4 JM-B CYT-1 isoform '
  - 'PIP5K1B '
  - 'FGF2(10-155) '
  - 'FOXO6 '
  - 'p-6Y-FRS2 '
  - p-S-AKT:PIP3
  - 'Neuregulins '
  - 'AKT1 '
  - CHUK
  - 'PIP4K2A '
  - CD28 family
  - CDKN1A,CDKN1B
  - 'PIK3CA '
  - PIP4K2 dimers
  - 'p-S472-AKT3 '
  - AKT1S1
  - 'p-Y546,Y584-PTPN11 '
  - RAC1:GTP,RAC2:GTP,RHOG:GTP
  - 'PPP2R5A '
  - p-S183,T246-AKT1S1
  - 'ESR2 '
  - 'FGF22 '
  - 'p-7Y-ERBB2 '
  license: CC0
  name: PIP3 activates AKT signaling
seo: CreativeWork
title: PIP3 activates AKT signaling
wpid: WP2653
---